Search for other papers by Jakub Supronik in
Google Scholar
PubMed
Search for other papers by Małgorzata Szelachowska in
Google Scholar
PubMed
Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland
Search for other papers by Adam Kretowski in
Google Scholar
PubMed
Search for other papers by Katarzyna Siewko in
Google Scholar
PubMed
Epidemiology, clinical presentation and pathophysiology Graves’ orbitopathy (GO), otherwise referred to as Graves’ eye disease or thyroid eye disease, is an autoimmune, inflammatory disorder of the retroocular tissue occurring in patients with
Department of Endocrinology, The People’s Hospital of Daxing District, Beijing, China
Search for other papers by Ya-Fen Hu in
Google Scholar
PubMed
Search for other papers by Lin Hua in
Google Scholar
PubMed
Search for other papers by Xiu Tuo in
Google Scholar
PubMed
Search for other papers by Ting-Ting Shi in
Google Scholar
PubMed
Search for other papers by Yi-Lin Yang in
Google Scholar
PubMed
Search for other papers by Yun-Fu Liu in
Google Scholar
PubMed
Search for other papers by Zhong-Yu Yan in
Google Scholar
PubMed
Search for other papers by Zhong Xin in
Google Scholar
PubMed
Introduction Graves’ orbitopathy (GO) or thyroid-associated ophthalmopathy (TAO) is an autoimmune inflammatory disease exerting severe functional and psychosocial influence. Approximately 30% of the patients with Graves’ disease (GD) develop
Search for other papers by Ru-Xuan Zhao in
Google Scholar
PubMed
Search for other papers by Ting-Ting Shi in
Google Scholar
PubMed
Search for other papers by Sha Luo in
Google Scholar
PubMed
Search for other papers by Yun-Fu Liu in
Google Scholar
PubMed
Search for other papers by Zhong Xin in
Google Scholar
PubMed
Search for other papers by Jin-Kui Yang in
Google Scholar
PubMed
Introduction Graves’ orbitopathy (GO) is an autoimmune disease which frequently arises in patients suffering from Graves’ disease ( 1 , 2 ). GO, often involving both eyes, is one of the most common orbital diseases in adults ( 3 , 4 ). GO
Search for other papers by Yue-Yue Wang in
Google Scholar
PubMed
Search for other papers by Qian Wu in
Google Scholar
PubMed
Search for other papers by Lu Chen in
Google Scholar
PubMed
Search for other papers by Wen Chen in
Google Scholar
PubMed
Search for other papers by Tao Yang in
Google Scholar
PubMed
Search for other papers by Xiao-Quan Xu in
Google Scholar
PubMed
Search for other papers by Fei-Yun Wu in
Google Scholar
PubMed
Search for other papers by Hao Hu in
Google Scholar
PubMed
Search for other papers by Huan-Huan Chen in
Google Scholar
PubMed
glucocorticoid for 12 weeks (0.5 g weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks) based on the European Group on Graves’ Orbitopathy consensus ( 2 ). Clinical assessment Disease duration was determined as the interval between the onset of TAO
Search for other papers by Waleed K W Al-Badri in
Google Scholar
PubMed
Search for other papers by Hinke Marijke Jellema in
Google Scholar
PubMed
Search for other papers by Arnaud R G G Potvin in
Google Scholar
PubMed
Search for other papers by Ruth M A van Nispen in
Google Scholar
PubMed
Search for other papers by Peter H Bisschop in
Google Scholar
PubMed
Search for other papers by Peerooz Saeed in
Google Scholar
PubMed
). Pertaining to GO severity (European Group on Graves’ Orbitopathy (EUGOGO) classification) two authors reported no significant link with depression in GO patients ( 13 , 72 , 79 ). In spite of that, in the study by Farid and colleagues, moderate to severe GO
Search for other papers by Xiaowen Zhang in
Google Scholar
PubMed
Department of Endocrinology and Metabolism, Drum Tower Clinical Medical College, Southeast University, Nanjing, China
Search for other papers by Chen Han in
Google Scholar
PubMed
Search for other papers by Hongwei Wang in
Google Scholar
PubMed
Search for other papers by Xinghong Sun in
Google Scholar
PubMed
Search for other papers by Xin Dou in
Google Scholar
PubMed
Search for other papers by Xueying He in
Google Scholar
PubMed
Search for other papers by Di Wu in
Google Scholar
PubMed
Search for other papers by Shanmei Shen in
Google Scholar
PubMed
Search for other papers by Dalong Zhu in
Google Scholar
PubMed
Search for other papers by Xinlin Zhang in
Google Scholar
PubMed
Search for other papers by Yan Bi in
Google Scholar
PubMed
Marcocci C Marino M Vaidya B Wiersinga WM & EUGOGO . The 2021 European Group on Graves’ Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy . European Journal of Endocrinology 2021 185 G43 – G67
Search for other papers by Marek Niedziela in
Google Scholar
PubMed
. Therefore, for safety reasons, a short-term clinical and laboratory follow-up (3–6 months) seems to be necessary to avoid missing a defined cause. Thyroid eye disease (thyroid orbitopathy) Thyroid orbitopathy (Graves’ orbitopathy) or thyroid eye
Department of Diabetes & Endocrinology, Skåne University Hospital, Malmö, Sweden
Search for other papers by Bushra Shahida in
Google Scholar
PubMed
Department of Diabetes & Endocrinology, Skåne University Hospital, Malmö, Sweden
Search for other papers by Tereza Planck in
Google Scholar
PubMed
Search for other papers by Tania Singh in
Google Scholar
PubMed
Department of Ophthalmology, Skåne University Hospital, Malmö, Sweden
Search for other papers by Peter Åsman in
Google Scholar
PubMed
Department of Diabetes & Endocrinology, Skåne University Hospital, Malmö, Sweden
Search for other papers by Mikael Lantz in
Google Scholar
PubMed
& Mourits MP . Effect of smoking on orbital fat and muscle volume in Graves’ orbitopathy . Thyroid 2011 21 177 – 181 . ( https://doi.org/10.1089/thy.2010.0218 ) 6 Wiersinga WM . Smoking and thyroid . Clinical Endocrinology 2013 79 145 – 151
Search for other papers by Selma Flora Nordqvist in
Google Scholar
PubMed
Search for other papers by Victor Brun Boesen in
Google Scholar
PubMed
Search for other papers by Åse Krogh Rasmussen in
Google Scholar
PubMed
Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed
Search for other papers by Steen Joop Bonnema in
Google Scholar
PubMed
Search for other papers by Per Karkov Cramon in
Google Scholar
PubMed
Department of Internal Medicine, Herlev Gentofte Hospital, Copenhagen, Denmark
Search for other papers by Torquil Watt in
Google Scholar
PubMed
Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark
Search for other papers by Mogens Groenvold in
Google Scholar
PubMed
National Research Centre for the Working Environment, Copenhagen, Denmark
QualityMetric Incorporated, LLC, Johnston, Rhode Island, USA
Search for other papers by Jakob Bue Bjorner in
Google Scholar
PubMed
Women 361 (83) Men 74 (17) Age (years) 54 (42–63) Diagnosis Nontoxic goiter 135 (31) Toxic nodular goiter 98 (23) Graves’ hyperthyroidism 73 (17) Graves’ orbitopathy (GO) 25 (6
Search for other papers by Clara Lundetoft Clausen in
Google Scholar
PubMed
Search for other papers by Åse Krogh Rasmussen in
Google Scholar
PubMed
Search for other papers by Trine Holm Johannsen in
Google Scholar
PubMed
Search for other papers by Linda Maria Hilsted in
Google Scholar
PubMed
Search for other papers by Niels Erik Skakkebæk in
Google Scholar
PubMed
Search for other papers by Pal Bela Szecsi in
Google Scholar
PubMed
Search for other papers by Lise Pedersen in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Thomas Benfield in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Anders Juul in
Google Scholar
PubMed
dysfunction as the state mimics the immune activation that accompanies inflammatory thyroid disease ( 10 ). A range of different cytokines have been linked to destructive thyroiditis ( 11 , 12 ), as well as Graves’ disease (GD) and Graves’ orbitopathy ( 13